

Supplementary Table 2. Responses of significantly altered metabolites among groups of patients with AKI and healthy controls

No.	Metabolite	m/z (mass/charge)	Retention time (sec)	Stage 1 AKI	Stage 2 AKI	Stage 3 AKI	Healthy controls	Mode
1	Unannotated	450.31	10.98	17.03	16.09	15.23	17.42	C-18 POS
2	Unannotated	762.59	21.2	22.00	22.01	22.76	21.07	C-18 POS
3	Unannotated	365.27	16.41	15.74	15.41	15.39	16.22	C18 NEG
4	Unannotated	401.29	19.14	16.5	16.79	17.25	15.98	C18 NEG
5	1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine	452.28	15	18.54	18.72	19.25	18.22	C18 NEG
6	1-Oleoyl-sn-glycero-3-phosphoethanolamine	478.29	15.43	17.82	18.17	18.45	17.48	C18 NEG
7	Unannotated	524.28	13.97	17.03	17.14	17.68	16.53	C18 NEG

Values of stages 1, 2, and 3 AKI as well as healthy controls represent log fold changes.
 AKI, acute kidney injury; POS, positive; NEG, negative.